Home Tags Topoisomerase I inhibitor

Tag: topoisomerase I inhibitor

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27%...

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics).This is the conclusion from an analysis of data from the pivotal...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in the US only) were presented...

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...